Dr Douglas Williams: new drugs and AI will fuel biotech boom
Dr Douglas Williams is a veteran senior executive and board member for several biotech companies. During his time at Biogen, ZymoGenetics, Amgen Immunex and Seattle Genetics, he was involved in the development of several multibillion-dollar treatments, including Enbrel, Tecfidera and Spinraza.
Matthew Partridge: The time and cost of clinical trials has been seen as one of the big stumbling blocks to the emergence of new drugs. Do you see any developments that could help speed up the process?
Douglas Williams: Anything you can do to speed up the process is beneficial – after all, time is money. I think the real benefits will come as we become more efficient at targeting better-defined populations of patients [those who meet highly specific and uniform criteria, thus making it easier to gauge the exact effect of drugs]. In a field with a high rate of failure, improving the chances of success by even a small percentage can have a huge impact on the bottom line.
Sign up to Money Morning
Don’t miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don’t miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Matthew Partridge: Have the recent changes at the US Food and Drug Administration (FDA), the regulator of federal health, helped or hindered the clinical-trial process?
Douglas Williams: It’s all a bit chaotic at present. You’re seeing reversals of long-standing policy with political interference in what should be scientifically driven decisions. The “willy-nilly” nature of the Department of Government Efficiency’s (DOGE) cuts has also led to a brain drain at the FDA itself, with some of the most experienced staff leaving.
Matthew Partridge: The FDA is seen as a gold standard when it comes to getting drugs approved first. Could there come a day when drug companies start looking to regulators in Europe or elsewhere?
Douglas Williams: This is already happening at the front end of the clinical-trial process, where Australia has become a key destination for early phase-one studies [the first of three stages of clinical trials, when scientists test the safety of the drug]. The regulatory process there is relatively quick and streamlined, making it a cost-effective place to run studies. And Australia’s consolidated healthcare system makes the process of finding patients and enrolling them in studies more efficient.
Similarly, I’ve been working with Chinese companies and the system’s low cost of capital, overall efficiency and rapid trial process are remarkable.
Matthew Partridge: The Trump administration has been threatening tariffs on drugs. Do you see geopolitical issues as a major risk for the drug and biotechnology sectors?
Douglas Williams: I do think there is logic in wanting to onshore some of the manufacturing for crucial drugs. There has been this enormous migration offshore from the US on the manufacturing side. So to try to bring some of that back, certainly for vital components of key drugs, makes a lot of sense. But there are surely better ways to achieve this than tariffs, which are a blunt instrument.
Matthew Partridge: Do you think America’s dominance of the biotech and drug sectors is at risk?
Douglas Williams: I think that it’s very much at risk for a variety of reasons. There definitely need to be some major changes to the FDA to bring the regulatory regime closer to what’s happening in China and Australia. Firms are moving to the latter for early-stage studies, although people will still want to enrol patients in later-stage trials in the US and Europe.
The other thing that’s happening in the US that I worry about from a longer-term perspective is that the reduction in the National Institutes of Health’s funding for basic science grants is chasing away a whole generation of PhD students and postdoctoral candidates. This is already starting to create a hole in the pipeline for talent, and the longer this goes on, even if it’s just for the four years of the current administration, the longer it will take to rebuild.
The engine driving the innovation that creates new companies in the sector and allows for new intellectual property to be created and new breakthroughs to take place is being eroded.
Matthew Partridge: What should the UK do to make itself more friendly to biotech and pharma companies?
Douglas Williams: The UK can streamline the process of starting studies and enrolling patients quickly and easily through the NHS, and raising patients’ awareness of the trials on offer. More specifically, it could learn a lot from what the Chinese have done around streamlining the rules governing which particular regulatory bodies you need to secure approval from to begin a trial.
Matthew Partridge: Turning to the wider sector, GLP-1 drugs are changing the way we deal with weight-loss, diabetes and perhaps other conditions as well. Do you think the firms that pioneered GLP-1s are going to be able to stay ahead of the competition, or will it be like the computer industry, where firms such as IBM were unable to maintain their control of the industry?
Douglas Williams: The biotech industry is based on the expectation that there will be a rotation of dominance, as patents only last a certain amount of time before rivals are allowed to produce generic versions of a drug, causing prices and profits to collapse. But until that happens, the first-movers in this area, such as Novo Nordisk and Eli Lily, will dominate it. They’ve also pursued new approaches for delivering the drug – shifting from injectables to oral tablets, for instance. So they’re creating scope for multiple waves of innovation, which could extend their dominance.
However, biotech is ultimately all about building a better mousetrap: there are other young companies coming in that are attempting new methods that don’t come with the side effects, such as muscle loss, that are associated with the GLP-1s, for instance.
Matthew Partridge: Are there any other big leaps forward that could take place in the next five years or so?
Douglas Williams: I find the work around the role of sleep in dementia and brain conditions very interesting, and the idea that deep sleep can help combat those conditions is certainly an elegant theory. Neurology, in general, has become much hotter from an investment perspective. I’m involved with several companies in the neuropsychiatry sector, including being chair of Draig Therapeutics, a Cardiff-based company developing treatments for major depressive disorder.
The analogy people have used is that neurology is going to become the next oncology, where the precision approach to well-defined populations of patients is going to dominate drug development. So, you’ll essentially be treating slices of the populations that have a particular broad definition of a disease.
Matthew Partridge: What about advances in medical imaging, such as MRIs and CT scans?
Douglas Williams: During my career, I was involved in the early development of some of the first approved drugs in the amyloid reduction arena and what really turned the tide was being able to understand what these drugs were doing inside the brain; it’s hard to do without some way of looking at the target. I think faster and more effective scanning technology has already fed back into neurology-drug development.
Matthew Partridge: Do you think in five years’ time the range of treatments for neurological conditions, things like dementia, could be radically different?
Douglas Williams: Yes, there’s so much activity in this area, a reflection of the problems posed by ageing populations.
Matthew Partridge: How is AI going to change drug development?
Douglas Williams: It depends on your definition of drug development. Taking the all-encompassing view, where a fully integrated company does the discovery, drug development, manufacturing and sales and marketing, it will change the whole process. One example is in manufacturing. Already, we can take real-time data from the bioreactors that are used to manufacture proteins, and AI can use this to tweak the process to make sure that you maximise productivity. There’s an increasing amount of work now on using AI in the clinical-trial process, both in terms of designing the trials and dealing with back-office operations.
I’ve been in this field for 40 years, and it’s remarkable what some of the young companies I’m involved in are doing with AI. I’m optimistic that in the next ten years, we’ll start to see the impact of AI on designing new molecules and finding new drugs too.
Matthew Partridge: Do you think that there will still be a need for actual scientists, rather than AI alone, to be involved?
Douglas Williams: Without question. If you ask ChatGPT or Claude a question, how the question is worded matters a lot, and that’s where the role of the scientist really shows itself – the better the question, the better the answer. So, there will always be a place for the human element in terms of driving science.
Matthew Partridge: Have investors in the sector learnt to tune out political noise and focus on the long-term growth story?
Douglas Williams: I think so. Stock market valuations have risen while mergers and acquisitions have proliferated, which is always healthy because it gives investors capital to put back to work. So a virtuous circle has developed. There’s never been a more amazing time in terms of the tools that we now have for drug development, while our understanding of biology continues to expand.
This article was first published in MoneyWeek’s magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
